| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1074-7613(00)80400-8 |
| P8608 | Fatcat ID | release_tbknpksn4fekvnqigadxagsima |
| P3181 | OpenCitations bibliographic resource ID | 2871338 |
| P698 | PubMed publication ID | 9430227 |
| P5875 | ResearchGate publication ID | 13800654 |
| P2093 | author name string | L Hood | |
| A Bookwalter | |||
| A Jasmin | |||
| J Murray | |||
| M Eby | |||
| P M Chaudhary | |||
| P2860 | cites work | A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain | Q24306835 |
| FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis | Q24307362 | ||
| RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death | Q24307376 | ||
| The receptor for the cytotoxic ligand TRAIL | Q24310481 | ||
| Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B | Q24312205 | ||
| TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. | Q24314730 | ||
| Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95 | Q24314819 | ||
| In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two FADD-like domains | Q24315787 | ||
| TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways | Q24317441 | ||
| The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation | Q24318742 | ||
| TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95) | Q24323902 | ||
| TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex | Q24329065 | ||
| Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death | Q24336389 | ||
| An antagonist decoy receptor and a death domain-containing receptor for TRAIL | Q28245153 | ||
| Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors | Q28245164 | ||
| FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death--inducing signaling complex | Q28283294 | ||
| A death-domain-containing receptor that mediates apoptosis | Q28297670 | ||
| Fas- and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus crmA gene product | Q28639862 | ||
| TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB | Q29614706 | ||
| An essential role for NF-kappaB in preventing TNF-alpha-induced cell death | Q29614707 | ||
| Suppression of TNF-alpha-induced apoptosis by NF-kappaB | Q29618717 | ||
| Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death | Q29620021 | ||
| The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death | Q29620519 | ||
| Interpreting cDNA sequences: some insights from studies on translation | Q30004215 | ||
| Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis | Q30080034 | ||
| Systematic mutational analysis of the death domain of the tumor necrosis factor receptor 1-associated protein TRADD. | Q33292436 | ||
| Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity | Q33497763 | ||
| Two TNF receptors | Q35231014 | ||
| Contenders in FasL/TNF death signaling | Q40530231 | ||
| FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis | Q41224805 | ||
| A novel domain within the 55 kd TNF receptor signals cell death | Q41528172 | ||
| Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. | Q46034718 | ||
| Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome | Q55670225 | ||
| Self-association of the Death Domains of the p55 Tumor Necrosis Factor (TNF) Receptor and Fas/APO1 Prompts Signaling for TNF and Fas/APO1 Effects | Q59707705 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | NF-κB | Q411114 |
| apoptotic process | Q14599311 | ||
| activation of NF-kappaB-inducing kinase activity | Q14859605 | ||
| TNF receptor superfamily member 10a | Q21116615 | ||
| TNF receptor superfamily member 10b | Q21135798 | ||
| P304 | page(s) | 821-30 | |
| P577 | publication date | 1997-12-01 | |
| P1433 | published in | Immunity | Q6005457 |
| P1476 | title | Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway | |
| P478 | volume | 7 |
| Q39686823 | A fifteen-amino-acid TVB peptide serves as a minimal soluble receptor for subgroup B avian leukosis and sarcoma viruses |
| Q33330494 | A logic-based diagram of signalling pathways central to macrophage activation |
| Q38319762 | A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase-independent cell death |
| Q30361915 | A set of NF-κB-regulated microRNAs induces acquired TRAIL resistance in lung cancer. |
| Q28272697 | APO2 ligand: a novel lethal weapon against malignant glioma? |
| Q44840688 | Actinomycin D renders cultured synovial fibroblasts susceptible to tumour necrosis factor related apoptosis-inducing ligand (TRAIL)-induced apoptosis |
| Q40811155 | Activation of protein kinase C inhibits TRAIL-induced caspases activation, mitochondrial events and apoptosis in a human leukemic T cell line |
| Q28139456 | Activation of the NF-kappaB pathway by caspase 8 and its homologs |
| Q40945791 | Activation of the c-Jun N-terminal kinase/stress-activated protein kinase pathway by overexpression of caspase-8 and its homologs |
| Q42653716 | Adenosine receptors control a new pathway of Fas-associated death domain protein expression regulation by secretion |
| Q40391803 | Adenovirus-mediated IKKbetaKA expression sensitizes prostate carcinoma cells to TRAIL-induced apoptosis |
| Q44976868 | An evolutionary conserved pathway of nuclear factor-kappaB activation involving caspase-mediated cleavage and N-end rule pathway-mediated degradation of IkappaBalpha |
| Q40354471 | Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model |
| Q39611397 | Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model. |
| Q40028104 | Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model |
| Q40150380 | Antibody gene therapy: an attractive approach for the treatment of cancers and other chronic diseases |
| Q33916097 | Antisense oligonucleotides as a tool for gene functionalization and target validation |
| Q36546533 | Antitumor Effect of Periplocin in TRAIL-Resistant Human Hepatocellular Carcinoma Cells through Downregulation of IAPs. |
| Q37425788 | Antitumor activity of TRAIL recombinant adenovirus in human malignant glioma cells |
| Q34532325 | Apo2L/TRAIL and its death and decoy receptors |
| Q41747264 | Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. |
| Q28176737 | Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy |
| Q35092230 | Apoptotic signaling cascades. |
| Q28143730 | Association of p130CAS with phosphatidylinositol-3-OH kinase mediates adenovirus cell entry |
| Q90687227 | Autophagy as a mechanism of Apo2L/TRAIL resistance |
| Q37289210 | Azadirone, a limonoid tetranortriterpene, induces death receptors and sensitizes human cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) through a p53 protein-independent mechanism: evidence for the role of the ROS-ERK- |
| Q34728945 | B lymphocytes are resistant to death receptor 5-induced apoptosis |
| Q36268430 | Bax/Bak-independent mitochondrial depolarization and reactive oxygen species induction by sorafenib overcome resistance to apoptosis in renal cell carcinoma |
| Q40477763 | Bid mediates apoptotic synergy between tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and DNA damage. |
| Q45883318 | Bifidobacterium longum as a delivery system of TRAIL and endostatin cooperates with chemotherapeutic drugs to inhibit hypoxic tumor growth |
| Q44009285 | Bisindolylmaleimide VIII enhances DR5-mediated apoptosis through the MKK4/JNK/p38 kinase and the mitochondrial pathways |
| Q37133814 | Breast tumor xenografts: diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody |
| Q35847699 | CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis |
| Q34266298 | CD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies |
| Q24291469 | CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells |
| Q77903149 | CD95(APO-1/Fas)-mediated apoptosis: live and let die |
| Q35969850 | CRISPR library designer (CLD): software for multispecies design of single guide RNA libraries |
| Q34082790 | Cell death control in lymphocytes. |
| Q39013916 | Cell death-independent activities of the death receptors CD95, TRAILR1, and TRAILR2. |
| Q35091128 | Cell surface Death Receptor signaling in normal and cancer cells |
| Q37003894 | Cells surviving fractional killing by TRAIL exhibit transient but sustainable resistance and inflammatory phenotypes |
| Q54537146 | Characterization of antioxidant and anti-inflammatory activities of bioactive fractions recovered from a glucose-lysine Maillard reaction model system. |
| Q37066527 | Characterization of the Interactions between Calmodulin and Death Receptor 5 in Triple-negative and Estrogen Receptor-positive Breast Cancer Cells: AN INTEGRATED EXPERIMENTAL AND COMPUTATIONAL STUDY. |
| Q35149525 | Characterization of the role of tumor necrosis factor apoptosis inducing ligand (TRAIL) in spermatogenesis through the evaluation of trail gene-deficient mice |
| Q40642496 | Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. |
| Q57220366 | Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells |
| Q40025662 | Cisplatin-mediated sensitivity to TRAIL-induced cell death in human granulosa tumor cells |
| Q22010649 | Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis |
| Q37038302 | Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects |
| Q37832083 | Combined modality therapy with TRAIL or agonistic death receptor antibodies. |
| Q33240972 | Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo |
| Q37761322 | Combining naturally occurring polyphenols with TNF-related apoptosis-inducing ligand: a promising approach to kill resistant cancer cells? |
| Q54002922 | Constitutive activation of nuclear factor-kappaB prevents TRAIL-induced apoptosis in renal cancer cells. |
| Q30896561 | Coordinated regulation of two TRAIL-R2/KILLER/DR5 mRNA isoforms by DNA damaging agents, serum and 17beta-estradiol in human breast cancer cells |
| Q39576979 | Cranberry proanthocyanidins mediate growth arrest of lung cancer cells through modulation of gene expression and rapid induction of apoptosis |
| Q34401648 | Critical role of interferon regulatory factor-1 in murine liver transplant ischemia reperfusion injury |
| Q36594908 | Current concepts in apoptosis: the physiological suicide program revisited. |
| Q44461620 | Cytotoxic drugs enhance the ex vivo sensitivity of malignant cells from a subset of acute myeloid leukaemia patients to apoptosis induction by tumour necrosis factor receptor-related apoptosis-inducing ligand |
| Q73787730 | Cytotoxicity of Tumor necrosis factor related apoptosis-inducing ligand towards Ewing's sarcoma cell lines |
| Q39982958 | DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design |
| Q33861644 | DR5 knockout mice are compromised in radiation-induced apoptosis |
| Q33939106 | DR5-mediated DISC controls caspase-8 cleavage and initiation of apoptosis in human glioblastomas. |
| Q35641622 | Death Receptor-Induced Apoptosis Signalling Regulation by Ezrin Is Cell Type Dependent and Occurs in a DISC-Independent Manner in Colon Cancer Cells |
| Q40816407 | Death domain mutagenesis of KILLER/DR5 reveals residues critical for apoptotic signaling |
| Q39138922 | Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration-effect relationship support clinical dose and regimen selection |
| Q48884086 | Death receptor 5 and neuroproliferation |
| Q34783540 | Death receptor-mediated apoptosis and the liver |
| Q35728318 | Death receptors 4 and 5 activate Nox1 NADPH oxidase through riboflavin kinase to induce reactive oxygen species-mediated apoptotic cell death |
| Q34490973 | Death receptors and apoptosis. Deadly signaling and evasive tactics |
| Q35743149 | Death receptors in chemotherapy and cancer |
| Q77716477 | Death receptors in liver biology and pathobiology |
| Q41959760 | Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer |
| Q78954628 | Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice |
| Q35543789 | Detection of Anticancer and Apoptotic Effect of the Produced IgYs against the Three Extracellular Domain of Human DR5 Protein |
| Q33999606 | Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. |
| Q38601765 | Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines. |
| Q34324018 | Direct binding of Fas-associated death domain (FADD) to the tumor necrosis factor-related apoptosis-inducing ligand receptor DR5 is regulated by the death effector domain of FADD. |
| Q39746249 | Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis |
| Q43294876 | Downregulation of cyclooxygenase-1 is involved in gastric mucosal apoptosis via death signaling in portal hypertensive rats |
| Q92526760 | Dysregulation of Intestinal Epithelial Cell RIPK Pathways Promotes Chronic Inflammation in the IBD Gut |
| Q64085914 | E3 ubiquitin ligases and deubiquitinases as modulators of TRAIL-mediated extrinsic apoptotic signaling pathway |
| Q36662230 | ERK mediated upregulation of death receptor 5 overcomes the lack of p53 functionality in the diaminothiazole DAT1 induced apoptosis in colon cancer models: efficiency of DAT1 in Ras-Raf mutated cells |
| Q30682911 | Early therapy assessment of combined anti-DR5 antibody and carboplatin in triple-negative breast cancer xenografts in mice using diffusion-weighted imaging and (1)H MR spectroscopy |
| Q37001575 | Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging |
| Q53570905 | Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. |
| Q40817486 | Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis |
| Q44009000 | Expression and prognostic value of FAS receptor/FAS ligand and TrailR1/TrailR2 in acute myeloid leukemia |
| Q51755661 | Expression of TRAIL and the death receptors DR4 and DR5 correlates with progression of degeneration in human intervertebral disks. |
| Q34929094 | Expression of TRAIL-splice variants in gastric carcinomas: identification of TRAIL-γ as a prognostic marker |
| Q34699537 | Expression of a broad array of negative costimulatory molecules and Blimp-1 in T cells following priming by HIV-1 pulsed dendritic cells |
| Q90382743 | FADD in Cancer: Mechanisms of Altered Expression and Function, and Clinical Implications |
| Q28609079 | FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2 |
| Q60188645 | Failure of Bcl-2 to block cytochrome c redistribution during TRAIL-induced apoptosis |
| Q40520855 | Fas ligand induces cell-autonomous NF-kappaB activation and interleukin-8 production by a mechanism distinct from that of tumor necrosis factor-alpha. |
| Q31120918 | Fas-associated protein with death domain (FADD)-independent recruitment of c-FLIPL to death receptor 5. |
| Q73500211 | Flow cytometric measurement of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in gastric epithelium and infiltrating mucosal lymphocytes in Helicobacter pylori-associated gastritis |
| Q28292767 | Following a TRAIL: update on a ligand and its five receptors |
| Q36685559 | Following the TRAIL to apoptosis |
| Q39205404 | Functional roles of tumor necrosis factor-related apoptosis-inducing ligand-DR5 interaction in B16F10 cells by activating the nuclear factor-κB pathway to induce metastatic potential |
| Q36743604 | Galectin-3 in apoptosis, a novel therapeutic target |
| Q39672002 | Gamma-tocotrienol promotes TRAIL-induced apoptosis through reactive oxygen species/extracellular signal-regulated kinase/p53-mediated upregulation of death receptors |
| Q53769683 | Gefitinib enhances human colon cancer cells to TRAIL-induced apoptosis of via autophagy- and JNK-mediated death receptors upregulation. |
| Q24292109 | Gene defect in ectodermal dysplasia implicates a death domain adapter in development |
| Q35127888 | Gene expression profiling associated with angiotensin II type 2 receptor-induced apoptosis in human prostate cancer cells |
| Q33713375 | Gene targeting in the analysis of mammalian apoptosis and TNF receptor superfamily signaling |
| Q35176314 | Genes and genomics of autoimmune inflammation: from Rel to TRAIL. |
| Q37481462 | Genetic and epigenetic inactivation of TNFRSF10C in human prostate cancer |
| Q84933235 | Genome-wide association study identifies two susceptibility loci for exudative age-related macular degeneration in the Japanese population |
| Q28394059 | Ginsenoside compound K sensitizes human colon cancer cells to TRAIL-induced apoptosis via autophagy-dependent and -independent DR5 upregulation |
| Q36656715 | HIV-1 immunopathogenesis: how good interferon turns bad. |
| Q34771715 | HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells |
| Q92084382 | Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists |
| Q92083766 | Higher-Order Clustering of the Transmembrane Anchor of DR5 Drives Signaling |
| Q73954834 | Hot on the TRAIL of acute promyelocytic leukemia |
| Q34572097 | How melanoma cells evade trail-induced apoptosis. |
| Q40181983 | Human Fanconi A cells are susceptible to TRAIL-induced apoptosis. |
| Q34664366 | Human immunodeficiency virus-1 (HIV-1)-mediated apoptosis: new therapeutic targets |
| Q33523440 | Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism |
| Q40623393 | Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2 |
| Q78423989 | Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis |
| Q39590450 | Identification and characterization of a shared TNFR-related receptor for subgroup B, D, and E avian leukosis viruses reveal cysteine residues required specifically for subgroup E viral entry. |
| Q90384448 | Identification of New DR5 Agonistic Nanobodies and Generation of Multivalent Nanobody Constructs for Cancer Treatment |
| Q33711437 | Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic. |
| Q34981970 | Immunobiology of tumor necrosis factor receptor superfamily |
| Q92756792 | Importance of TRAIL Molecular Anatomy in Receptor Oligomerization and Signaling. Implications for Cancer Therapy |
| Q36368009 | In autoimmune diabetes the transition from benign to pernicious insulitis requires an islet cell response to tumor necrosis factor alpha. |
| Q40463099 | Increased sensitivity to TRAIL-induced apoptosis occurs during the adenoma to carcinoma transition of colorectal carcinogenesis. |
| Q34146806 | Inducible resistance to Fas-mediated apoptosis in B cells |
| Q43796884 | Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma |
| Q40910706 | Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not growth arrest |
| Q22010404 | Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II |
| Q54020370 | Inhibition of NF-kappaB activity enhances TRAIL mediated apoptosis in breast cancer cell lines. |
| Q39710105 | Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin |
| Q33844897 | Inhibition of TRAIL-induced apoptosis and forced internalization of TRAIL receptor 1 by adenovirus proteins |
| Q40521747 | Inhibition of the NF-kappaB pathway enhances TRAIL-mediated apoptosis in neuroblastoma cells |
| Q62391840 | Interferon-γ Sensitizes Human Myeloid Leukemia Cells to Death Receptor-mediated Apoptosis by a Pleiotropic Mechanism |
| Q41000355 | Interleukin-1 protects transformed keratinocytes from tumor necrosis factor-related apoptosis-inducing ligand |
| Q38924056 | Intracellular localization of DR5 and related regulatory pathways as a mechanism of resistance to TRAIL in cancer |
| Q36597952 | Intracellular signals and events activated by cytokines of the tumor necrosis factor superfamily: From simple paradigms to complex mechanisms. |
| Q36366424 | Intracellular-signaling tumor-regression modeling of the pro-apoptotic receptor agonists dulanermin and conatumumab |
| Q35170993 | Involvement of general control nonderepressible kinase 2 in cancer cell apoptosis by posttranslational mechanisms |
| Q45122713 | Involvement of tumor necrosis factor-alpha receptor 1 and tumor necrosis factor-related apoptosis-inducing ligand-(TRAIL) receptor-2/DR-5, but not Fas, in graft injury in live-donor liver transplantation |
| Q74419330 | Involvement of tumour necrosis factor-alpha-related apoptosis-inducing ligand in enhanced cytotoxicity of lipopolysaccharide-stimulated dendritic cells to activated T cells |
| Q38557486 | Journey of TRAIL from Bench to Bedside and its Potential Role in Immuno-Oncology. |
| Q90481183 | Knock down of Fas-Associated Protein with Death Domain (FADD) Sensitizes Osteosarcoma to TNFα-induced Cell Death |
| Q33823295 | Large-scale analysis of UPR-mediated apoptosis in human cells. |
| Q40766198 | Localization of Knops system antigens in the long homologous repeats of complement receptor 1. |
| Q90196428 | MSC.sTRAIL Has Better Efficacy than MSC.FL-TRAIL and in Combination with AKTi Blocks Pro-Metastatic Cytokine Production in Prostate Cancer Cells |
| Q33909572 | Maternal plasma soluble TRAIL is decreased in preeclampsia |
| Q38008400 | Mechanisms and biomarkers of apoptosis in liver disease and fibrosis |
| Q35954258 | Mechanisms of resistance to TRAIL-induced apoptosis in cancer |
| Q43554036 | Melittin, a major component of bee venom, sensitizes human hepatocellular carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by activating CaMKII-TAK1-JNK/p38 and inhibiting IkappaBalpha kinase-NFkap |
| Q50866811 | Membrane expression of the death ligand trail receptors DR4 and DR5 in the normal endometrium, endometrial atypical hyperplasia and endometrioid endometrial cancer. |
| Q40421605 | Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis |
| Q36401247 | Mitogen-activated protein kinase kinase antagonized fas-associated death domain protein-mediated apoptosis by induced FLICE-inhibitory protein expression |
| Q34393708 | Modeling dynamics of cell-to-cell variability in TRAIL-induced apoptosis explains fractional killing and predicts reversible resistance |
| Q35756863 | Modulation of TRAIL signaling complex. |
| Q35756898 | Modulation of TRAIL signaling for cancer therapy |
| Q28145950 | Modulation of the NF-kappa B pathway by virally encoded death effector domains-containing proteins |
| Q40957476 | Modulation of tumor necrosis factor and interleukin-1-dependent NF-kappaB activity by mPLK/IRAK. |
| Q40791420 | Modulation of tumor necrosis factor apoptosis-inducing ligand- induced NF-kappa B activation by inhibition of apical caspases |
| Q47604133 | Molecular dynamics study of peptide segments of the BH3 domain of the proapoptotic proteins Bak, Bax, Bid and Hrk bound to the Bcl-xL and Bcl-2 proteins. |
| Q34577074 | Molecular mechanisms for apoptosis induced by signaling through the B cell antigen receptor |
| Q38091548 | Molecular signatures of T-cell inhibition in HIV-1 infection |
| Q28505689 | Mouse receptor interacting protein 3 does not contain a caspase-recruiting or a death domain but induces apoptosis and activates NF-kappaB |
| Q39633869 | Myxoma Virus Induces Ligand Independent Extrinsic Apoptosis in Human Myeloma Cells |
| Q40468711 | NFkappaB-mediated upregulation of bcl-xl restrains TRAIL-mediated apoptosis in murine viral hepatitis. |
| Q36401340 | Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells |
| Q38966071 | Neutralization Versus Reinforcement of Proinflammatory Cytokines to Arrest Autoimmunity in Type 1 Diabetes |
| Q40661645 | Neutralization of TRAIL death pathway protects human neuronal cell line from beta-amyloid toxicity |
| Q34022690 | New insights into apoptosis signaling by Apo2L/TRAIL. |
| Q38440186 | Nicotine-induced protein expression profiling reveals mutually altered proteins across four human cell lines |
| Q38098380 | Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family |
| Q39861453 | Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis |
| Q35027622 | On the TRAIL to apoptosis |
| Q36863153 | On the TRAIL to therapeutic intervention in liver disease |
| Q26768160 | Onto better TRAILs for cancer treatment |
| Q38315460 | Osteoblasts display different responsiveness to TRAIL-induced apoptosis during their differentiation process |
| Q46824166 | Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis |
| Q48341610 | PU.1 supports TRAIL-induced cell death by inhibiting NF-κB-mediated cell survival and inducing DR5 expression. |
| Q33906524 | Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5) |
| Q40341132 | Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma |
| Q37351154 | Potentiation of TRAIL killing activity by multimerization through isoleucine zipper hexamerization motif |
| Q31163344 | Preparation and functional studies of hydroxyethyl chitosan nanoparticles loaded with anti-human death receptor 5 single-chain antibody |
| Q33637350 | Prognostic significance of TMEM16A, PPFIA1, and FADD expression in invasive ductal carcinoma of the breast |
| Q39812804 | Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer. |
| Q38601593 | Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy |
| Q40214366 | Prospective antitumor effects of the combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin against esophageal squamous cell carcinoma |
| Q37451204 | Protein kinase Cδ and caspase‐3 modulate TRAIL‐induced apoptosis in breast tumor cells |
| Q38611114 | RIPK1 protects hepatocytes from death in Fas-induced hepatitis |
| Q40890162 | Rapid B cell apoptosis induced by antigen receptor ligation does not require Fas (CD95/APO-1), the adaptor protein FADD/MORT1 or CrmA-sensitive caspases but is defective in both MRL-+/+ and MRL-lpr/lpr mice |
| Q34561798 | Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants. |
| Q34109567 | Receptor-interacting protein (RIP) kinase family. |
| Q34274842 | Receptor-mediated choreography of life and death. |
| Q35480734 | Regulating TRAIL receptor-induced cell death at the membrane : a deadly discussion |
| Q34014711 | Regulation of TNF-related apoptosis-inducing ligand on primary CD4+ T cells by HIV-1: role of type I IFN-producing plasmacytoid dendritic cells |
| Q35756929 | Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors |
| Q73704115 | Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB |
| Q35756915 | Regulation of sensitivity to TRAIL by the PTEN tumor suppressor. |
| Q55340117 | Relationship between the agonist activity of synthetic ligands of TRAIL-R2 and their cell surface binding modes. |
| Q79302950 | Resistance of infant leukemia with MLL rearrangement to tumor necrosis factor-related apoptosis-inducing ligand: a possible mechanism for poor sensitivity to antitumor immunity |
| Q44040278 | Resistance of mitochondrial DNA-deficient cells to TRAIL: role of Bax in TRAIL-induced apoptosis |
| Q40471436 | Resistance to Apo2 ligand (Apo2L)/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis and constitutive expression of Apo2L/TRAIL in human T-cell leukemia virus type 1-infected T-cell lines. |
| Q24683245 | Respiratory syncytial virus infection sensitizes cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand |
| Q34333852 | Role of Bcl-xL/Beclin-1 in synergistic apoptotic effects of secretory TRAIL-armed adenovirus in combination with mitomycin C and hyperthermia on colon cancer cells |
| Q28076798 | Role of nanotechnology and gene delivery systems in TRAIL-based therapies |
| Q33855449 | Safety and antitumor activity of recombinant soluble Apo2 ligand |
| Q47168390 | Secretory stressors induce intracellular death receptor accumulation to control apoptosis. |
| Q40038240 | Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis. |
| Q73347788 | Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan |
| Q55471801 | Sensitization of human glioblastomas to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by NF-kappaB inhibitors. |
| Q35003696 | Shiga toxin 2-induced endoplasmic reticulum stress is minimized by activated protein C but does not correlate with lethal kidney injury. |
| Q51760860 | Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy. |
| Q39050974 | Sialic acid-binding lectin (leczyme) induces apoptosis to malignant mesothelioma and exerts synergistic antitumor effects with TRAIL. |
| Q33782305 | Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors |
| Q58883548 | Signalling by proteolysis: death receptors induce apoptosis |
| Q34297762 | Snake venom toxin from Vipera lebetina turanica induces apoptosis of colon cancer cells via upregulation of ROS- and JNK-mediated death receptor expression |
| Q33910907 | Soluble TRAIL in normal pregnancy and acute pyelonephritis: a potential explanation for the susceptibility of pregnant women to microbial products and infection |
| Q36401557 | Stimulus-dependent synergism of the antiapoptotic tumor necrosis factor receptor-associated factor 2 (TRAF2) and nuclear factor kappaB pathways |
| Q37826107 | Structural analyses of death domains and their interactions |
| Q48319204 | Structural principles of tumor necrosis factor superfamily signaling |
| Q24810732 | Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells |
| Q48035885 | Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cells |
| Q39888618 | Susceptibility of the C2 canine mastocytoma cell line to the effects of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). |
| Q44389071 | Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway |
| Q35148616 | Systemic lupus erythematosus and apoptosis: a question of balance |
| Q22254092 | TAJ, a novel member of the tumor necrosis factor receptor family, activates the c-Jun N-terminal kinase pathway and mediates caspase-independent cell death |
| Q30578474 | TNF receptor associated factors in cytokine signaling. |
| Q35591708 | TRAIL and apoptosis induction by TNF-family death receptors. |
| Q35756909 | TRAIL and chemotherapeutic drugs in cancer therapy |
| Q43861815 | TRAIL and inhibitors of apoptosis are opposing determinants for NF-kappaB-dependent, genotoxin-induced apoptosis of cancer cells |
| Q35756919 | TRAIL and malignant glioma. |
| Q80931422 | TRAIL and thymocyte apoptosis: not so deadly? |
| Q35756895 | TRAIL and viral infection |
| Q37307340 | TRAIL gene therapy: from preclinical development to clinical application |
| Q34291312 | TRAIL in cancer therapy: present and future challenges |
| Q39852876 | TRAIL receptor mediates inflammatory cytokine release in an NF-kappaB-dependent manner |
| Q36572530 | TRAIL receptor-targeted therapy. |
| Q99408898 | TRAIL signals, extracellular matrix and vessel remodelling |
| Q35624736 | TRAIL, Bim, and thymic-negative selection |
| Q37072767 | TRAIL, DR4 and DR5 are upregulated in kidneys from patients with lupus nephritis and exert proliferative and proinflammatory effects |
| Q64266102 | TRAIL, OPG, and TWEAK in kidney disease: biomarkers or therapeutic targets? |
| Q36590964 | TRAIL, caspases and maturation of normal and leukemic myeloid precursors |
| Q38811508 | TRAIL-R2 Superoligomerization Induced by Human Monoclonal Agonistic Antibody KMTR2. |
| Q38352891 | TRAIL-based therapy in pediatric bone tumors: how to overcome resistance |
| Q28204941 | TRAIL-induced apoptosis is independent of the mitochondrial apoptosis mediator DAP3 |
| Q35681794 | TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill. |
| Q34482821 | TRAIL/Apo-2L: mechanisms and clinical applications in cancer |
| Q40992331 | TRAIL/Apo2L activates c-Jun NH2-terminal kinase (JNK) via caspase-dependent and caspase-independent pathways |
| Q77485552 | TRAIL: a molecule with multiple receptors and control mechanisms |
| Q92757990 | TRAILblazing Strategies for Cancer Treatment |
| Q28512952 | TROY, a newly identified member of the tumor necrosis factor receptor superfamily, exhibits a homology with Edar and is expressed in embryonic skin and hair follicles |
| Q52531761 | Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. |
| Q90590454 | Targeting apoptosis in cancer therapy |
| Q38202818 | Targeting neutrophil apoptosis for enhancing the resolution of inflammation |
| Q35184968 | Targeting the tumor necrosis factor-related apoptosis-inducing ligand path in neuroblastoma |
| Q40510248 | The C-terminal tails of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas receptors have opposing functions in Fas-associated death domain (FADD) recruitment and can regulate agonist-specific mechanisms of receptor activation |
| Q34230758 | The Fas signaling connection between autoimmunity and embryonic lethality |
| Q39223220 | The Impact of the Interferon/TNF-Related Apoptosis-Inducing Ligand Signaling Axis on Disease Progression in Respiratory Viral Infection and Beyond |
| Q73104338 | The TRAIL DISCussion: It is FADD and caspase-8! |
| Q37278043 | The TRAIL apoptotic pathway in cancer onset, progression and therapy |
| Q36511919 | The TRAIL to targeted therapy of breast cancer |
| Q35146349 | The TRAIL to viral pathogenesis: the good, the bad and the ugly |
| Q39253903 | The adaptor protein FADD and the initiator caspase-8 mediate activation of NF-κB by TRAIL. |
| Q34827734 | The adaptor protein TRADD is essential for TNF-like ligand 1A/death receptor 3 signaling |
| Q33965358 | The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase |
| Q42067854 | The death domain of FADD is essential for embryogenesis, lymphocyte development, and proliferation |
| Q28186582 | The death effector domain protein family |
| Q36662104 | The death ligand TRAIL in diabetic nephropathy |
| Q53988288 | The differential sensitivity of Bc1-2-overexpressing human breast tumor cells to TRAIL or doxorubicin-induced apoptosis is dependent on Bc1-2 protein levels. |
| Q28141467 | The ectodermal dysplasia receptor activates the nuclear factor-kappaB, JNK, and cell death pathways and binds to ectodysplasin A |
| Q36653062 | The pro-apoptotic effects of TIPE2 on AA rat fibroblast-like synoviocytes via regulation of the DR5-caspase-NF-κB pathway in vitro |
| Q34682495 | The role of TRADD in TRAIL-induced apoptosis and signaling |
| Q36920268 | The role of TRADD in death receptor signaling |
| Q36295655 | The role of apoptosis in the development and function of T lymphocytes |
| Q36302070 | The signaling and apoptotic effects of TNF-related apoptosis-inducing ligand in HIV-1 associated dementia |
| Q35836872 | The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention |
| Q37114025 | Therapeutic applications of TRAIL receptor agonists in cancer and beyond |
| Q46181439 | Three adenovirus E3 proteins cooperate to evade apoptosis by tumor necrosis factor-related apoptosis-inducing ligand receptor-1 and -2. |
| Q52087398 | Transgenic overexpression of a dominant negative mutant of FADD that, although counterselected during tumor progression, cooperates in L-myc-induced tumorigenesis. |
| Q36968192 | Triple bioluminescence imaging for in vivo monitoring of cellular processes. |
| Q28213249 | Tumor necrosis factor-alpha induces the expression of DR6, a member of the TNF receptor family, through activation of NF-kappaB |
| Q36368539 | Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression |
| Q40675663 | Tumor necrosis factor-related apoptosis-inducing ligand enhances collagen production by human lung fibroblasts |
| Q34272896 | Tumor necrosis factor-related apoptosis-inducing ligand induces caspase-dependent interleukin-8 expression and apoptosis in human astroglioma cells |
| Q36058434 | Tumor necrosis factor-related apoptosis-inducing ligand induces the expression of proinflammatory cytokines in macrophages and re-educates tumor-associated macrophages to an antitumor phenotype |
| Q28215810 | Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells |
| Q37355548 | Tumor-targeted delivery of a C-terminally truncated FADD (N-FADD) significantly suppresses the B16F10 melanoma via enhancing apoptosis |
| Q40789234 | Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. |
| Q43004119 | Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake |
| Q37486214 | Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in central nervous system inflammation |
| Q39899167 | Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced chemokine release in both TRAIL-resistant and TRAIL-sensitive cells via nuclear factor kappa B. |
| Q39605825 | Two functionally distinct forms of a retroviral receptor explain the nonreciprocal receptor interference among subgroups B, D, and E avian leukosis viruses |
| Q39214017 | Ubiquitination by the membrane-associated RING-CH-8 (MARCH-8) ligase controls steady-state cell surface expression of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) receptor 1. |
| Q54393855 | Understanding the conservation patterns and molecular phylogenetics of human death receptors family through computational biology. |
| Q36576268 | Volumetric contrast-enhanced ultrasound imaging to assess early response to apoptosis-inducing anti-death receptor 5 antibody therapy in a breast cancer animal model |
| Q42487048 | Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. |
| Q33658266 | X-linked ectodermal dysplasia receptor is downregulated in breast cancer via promoter methylation |
| Q64095096 | Xanthohumol increases death receptor 5 expression and enhances apoptosis with the TNF-related apoptosis-inducing ligand in neuroblastoma cell lines |
| Q40608578 | Xenopus death receptor-M1 and -M2, new members of the tumor necrosis factor receptor superfamily, trigger apoptotic signaling by differential mechanisms |
| Q39892148 | ZFAT is an antiapoptotic molecule and critical for cell survival in MOLT-4 cells |
| Q37341171 | Zerumbone enhances TRAIL-induced apoptosis through the induction of death receptors in human colon cancer cells: Evidence for an essential role of reactive oxygen species. |
| Q22010238 | c-E10 is a caspase-recruiting domain-containing protein that interacts with components of death receptors signaling pathway and activates nuclear factor-kappaB |
| Q24299363 | Role of activating transcription factor 3 (ATF3) in endoplasmic reticulum (ER) stress-induced sensitization of p53-deficient human colon cancer cells to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis through |
Search more.